BRPI0816784A2 - Fatores neuro-endócrinos para o tratamento de doenças degenerativas - Google Patents

Fatores neuro-endócrinos para o tratamento de doenças degenerativas

Info

Publication number
BRPI0816784A2
BRPI0816784A2 BRPI0816784A BRPI0816784A2 BR PI0816784 A2 BRPI0816784 A2 BR PI0816784A2 BR PI0816784 A BRPI0816784 A BR PI0816784A BR PI0816784 A2 BRPI0816784 A2 BR PI0816784A2
Authority
BR
Brazil
Prior art keywords
treatment
degenerative diseases
neuroendocrine factors
neuroendocrine
factors
Prior art date
Application number
Other languages
English (en)
Inventor
Anja Bosserhoff
Thomas Schubert
Elisabeth Hustert
Original Assignee
Scil Technology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by Scil Technology Gmbh filed Critical Scil Technology Gmbh
Publication of BRPI0816784A2 publication Critical patent/BRPI0816784A2/pt
Publication of BRPI0816784A8 publication Critical patent/BRPI0816784A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0816784A 2007-09-14 2008-09-12 Fatores neuro-endócrinos para o tratamento de doenças degenerativas BRPI0816784A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP08006810 2008-04-03
PCT/EP2008/007579 WO2009033715A2 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Publications (2)

Publication Number Publication Date
BRPI0816784A2 true BRPI0816784A2 (pt) 2015-03-24
BRPI0816784A8 BRPI0816784A8 (pt) 2016-01-19

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816784A BRPI0816784A8 (pt) 2007-09-14 2008-09-12 Fatores neuro-endócrinos para o tratamento de doenças degenerativas

Country Status (13)

Country Link
US (1) US20110002972A1 (pt)
EP (1) EP2212344B1 (pt)
JP (1) JP2010539123A (pt)
KR (1) KR20100075493A (pt)
CN (1) CN101821283A (pt)
AU (1) AU2008297889A1 (pt)
BR (1) BRPI0816784A8 (pt)
CA (1) CA2699411A1 (pt)
MX (1) MX2010002716A (pt)
NZ (1) NZ583851A (pt)
RU (1) RU2496790C2 (pt)
WO (1) WO2009033715A2 (pt)
ZA (1) ZA201001644B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
AR084541A1 (es) * 2010-12-23 2013-05-22 Sanofi Sa PROTEINA DE FUSION ROBO1-Fc PARA SU USO EN EL TRATAMIENTO DEL HEPATOCARCINOMA
EP3653218B1 (en) * 2011-07-04 2024-12-18 Mesoblast, Inc. Treating or preventing rheumatic disease
WO2013187730A1 (ko) * 2012-06-15 2013-12-19 재단법인 아산사회복지재단 Ｓｌｉｔ-Ｒｏｂｏ 시스템을 이용한 골절 또는 골다공증의 예방 또는 치료용 조성물
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
JPWO2015072527A1 (ja) * 2013-11-13 2017-03-16 国立大学法人大阪大学 ネトリン１含有破骨細胞形成抑制剤
PL3116521T3 (pl) 2014-03-14 2024-12-16 The Research Foundation For The State University Of New York Neurogeniczna regulacja wzrostu i degradacji kości
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US20200397860A1 (en) * 2018-02-14 2020-12-24 Cornell University Slit and bone growth modulation
BR112021016948A2 (pt) * 2019-02-27 2021-11-03 Daewoong Pharmaceutical Co Ltd Composição que compreende lrrd2 ligado à albumina de proteína slit3 para prevenção ou tratamento de doenças relacionadas a ossos e uso de lrrd2 ligado à albumina da proteína slit3
KR20220079857A (ko) * 2019-09-13 2022-06-14 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 Aav-상용성 라미닌-링커 중합 단백질
CN110841057B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
US20240277861A1 (en) * 2021-07-26 2024-08-22 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6342370B1 (en) * 1997-10-31 2002-01-29 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US6924355B2 (en) * 1998-09-01 2005-08-02 Genentech, Inc. PRO1343 polypeptides
AU3755100A (en) * 1999-03-17 2000-10-04 Washington University Vertebrate slit dna sequence, protein and uses thereof
AU2001278655A1 (en) * 2000-07-18 2002-01-30 Compugen Ltd. Novel nucleic acid and amino acid sequences
EP1307557A2 (en) * 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
CA2423519A1 (en) * 2000-08-10 2002-02-14 Pharmacia Corporation A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
US20060025335A1 (en) * 2004-01-30 2006-02-02 Kinane Thomas B Netrin compositions and methods of using the same
CN101600451A (zh) * 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法

Also Published As

Publication number Publication date
BRPI0816784A8 (pt) 2016-01-19
WO2009033715A2 (en) 2009-03-19
AU2008297889A1 (en) 2009-03-19
MX2010002716A (es) 2010-07-05
RU2010114713A (ru) 2011-10-20
RU2496790C2 (ru) 2013-10-27
ZA201001644B (en) 2011-03-30
EP2212344B1 (en) 2014-03-26
EP2212344A2 (en) 2010-08-04
KR20100075493A (ko) 2010-07-02
WO2009033715A3 (en) 2010-03-18
US20110002972A1 (en) 2011-01-06
CN101821283A (zh) 2010-09-01
JP2010539123A (ja) 2010-12-16
NZ583851A (en) 2012-06-29
CA2699411A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25A Requested transfer of rights approved

Owner name: FORMYCON GMBH (DE)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.